CT47A4: A Potential Drug Target for Cancer (G728075)

Target Name: CT47A4

NCBI ID: G728075

CT47A4

CT47A4: A Potential Drug Target for Cancer

Cancer/testis antigen 47 (CT47A4) is a protein that is expressed in a variety of tissues throughout the body, including the breast, lung, and gastrointestinal tract. It is also a key protein expressed in the testes, which are the primary sites of cancer development in men. As a result, CT47A4 has been identified as a potential drug target for cancer treatment.

The protein encoded by CT47A4 is a member of the CD27 superfamily, which includes proteins that are involved in cell-cell adhesion, signaling, and inflammation. It is characterized by a single extracellular domain that consists of a single transmembrane region and a cytoplasmic tail. The cytoplasmic tail is composed of a single polypeptide chain that contains a variety of conserved structural elements, including a long coiled-coil region and a terminal glycylated cysteine residue.

CT47A4 is expressed in a variety of tissues throughout the body, including the breast, lung, and gastrointestinal tract. It is also expressed in the testes, which are the primary sites of cancer development in men. In the breast, CT47A4 is expressed in the epithelial cells, which line the breast tissue and are responsible for producing milk. In the lung, CT47A4 is expressed in the epithelial cells that line the airways of the lungs. In the gastrointestinal tract, CT47A4 is expressed in the epithelial cells that line the digestive tract.

The function of CT47A4 is not well understood, but it is believed to play a role in cell signaling and adhesion. It is part of a signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. This pathway is known as the TGF-β pathway, which is a well-established mechanism for cancer development.

In addition to its role in cell signaling, CT47A4 is also thought to be involved in the development and progression of cancer. It has been shown to be involved in the regulation of cell cycle progression, cell survival, and angiogenesis. It is also involved in the regulation of inflammation, which is a key aspect of cancer progression.

Given its potential role in cancer development and progression, CT47A4 has been identified as a potential drug target for cancer treatment. Many studies have shown that inhibiting CT47A4 can have a variety of therapeutic effects, including the inhibition of cancer cell growth, the inhibition of cancer cell migration, and the inhibition of cancer cell angiogenesis.

One approach to inhibiting CT47A4 is to target its expression. This can be done using small molecules, such as drugs that inhibit the activity of transcription factors, such as PD-L1. These drugs have been shown to be effective in inhibiting the expression of CT47A4 in cancer cells. Another approach to inhibiting CT47A4 is to target its function. This can be done using antibodies that specifically recognize and inhibit CT47A4, such as monoclonal antibodies (MAs) or chimeric antibodies.

In addition to its potential as a drug target, CT47A4 also has potential as a biomarker for cancer diagnosis and monitoring. Its expression has been shown to be sensitive to a variety of therapeutic interventions, including chemotherapy, radiation therapy, and targeted therapies. This makes it a promising biomarker for the diagnosis and monitoring of cancer.

Overall, CT47A4 is a protein that is expressed in a variety of tissues throughout the body and has been identified as a potential drug target for cancer treatment. Its role in cell signaling and adhesion, as well as its involvement in cancer development and progression, make it an attractive target for therapeutic intervention. Further research is needed to fully understand its function and potential as a drug

Protein Name: Cancer/testis Antigen Family 47 Member A4

The "CT47A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets